Systemic cyclosporin A and tacrolimus are effective treatments for psoriasis. Cyclosporin A and tacrolimus block T cell activation by inhibiting the phosphatase calcineurin and preventing translocation from the cytoplasm to the nucleus of the transcription factor nuclear factor of activated T cells (NFAT). Inhibition of T cell activation is thought to account for their therapeutic action in psoriasis. We investigated whether nonimmune cells in human skin express calcineurin and NFAT1 and whether cyclosporin A and tacrolimus block activation of calcineurin/NFAT in epidermal keratinocytes. The expression patterns of the principal components of calcineurin/NFAT signaling pathway in normal human skin and psoriasis were determined by immunohistochemistry. We assessed calcineurin/NFAT activation in cultured keratinocytes by measuring the degree of nuclear localization of calcineurin and NFAT1 using immuno¯uorescence/confocal microscopy and assessed if cyclosporin A and tacrolimus blocked nuclear translocation of these proteins. A variety of cell types in normal and psoriatic skin expressed calcineurin and NFAT1, but expression was particularly prominent in keratinocytes. The principal cyclosporin A and tacrolimus binding proteins cyclophilin A and FKBP12 were also expressed by keratinocytes and nonimmune cells in skin. NFAT1 was predominantly nuclear in normal basal epidermal keratinocytes. Increased nuclear localization of NFAT1 was observed in suprabasal keratinocytes within lesional and to a lesser extent nonlesional psoriatic epidermis compared to normal skin (p = 0.001 and p = 0.03, respectively), suggesting increased activation of calcineurin in psoriatic epidermal keratinocytes. Agonists that induce keratinocyte differentiation, speci®cally 12±0-tetradecanoyl-phorbol-13-acetate (TPA) plus ionomycin, TPA, and raised extracellular calcium, induced nuclear translocation of NFAT1 and calcineurin in keratinocytes that was inhibited by pretreatment with cyclosporin A or tacrolimus. In contrast in human dermal ®broblasts, TPA plus ionomycin or TPA did not signi®cantly alter the proportion of nuclear-associated NFAT1. These data provide the ®rst evidence that calcineurin is functionally active in human keratinocytes inducing nuclear translocation of NFAT1 and also indicate that regulation of NFAT1 nuclear translocation in skin is cell type spe-ci®c. Inhibition of this pathway in epidermal keratinocytes may account, in part, for the therapeutic effect of cyclosporin A and tacrolimus in skin diseases such as psoriasis.
Systemic cyclosporin A and tacrolimus are effective treatments for psoriasis. Cyclosporin A and tacrolimus block T cell activation by inhibiting the phosphatase calcineurin and preventing translocation from the cytoplasm to the nucleus of the transcription factor nuclear factor of activated T cells (NFAT) . Inhibition of T cell activation is thought to account for their therapeutic action in psoriasis. We investigated whether nonimmune cells in human skin express calcineurin and NFAT1 and whether cyclosporin A and tacrolimus block activation of calcineurin/NFAT in epidermal keratinocytes. The expression patterns of the principal components of calcineurin/NFAT signaling pathway in normal human skin and psoriasis were determined by immunohistochemistry. We assessed calcineurin/NFAT activation in cultured keratinocytes by measuring the degree of nuclear localization of calcineurin and NFAT1 using immuno¯uorescence/confocal microscopy and assessed if cyclosporin A and tacrolimus blocked nuclear translocation of these proteins. A variety of cell types in normal and psoriatic skin expressed calcineurin and NFAT1, but expression was particularly prominent in keratinocytes. The principal cyclosporin A and tacrolimus binding proteins cyclophilin A and FKBP12 were also expressed by keratinocytes and nonimmune cells in skin. NFAT1 was predominantly nuclear in normal basal epidermal keratinocytes. Increased nuclear localization of NFAT1 was observed in suprabasal keratinocytes within lesional and to a lesser extent nonlesional psoriatic epidermis compared to normal skin (p = 0.001 and p = 0.03, respectively), suggesting increased activation of calcineurin in psoriatic epidermal keratinocytes. Agonists that induce keratinocyte differentiation, speci®cally 12±0-tetradecanoyl-phorbol-13-acetate (TPA) plus ionomycin, TPA, and raised extracellular calcium, induced nuclear translocation of NFAT1 and calcineurin in keratinocytes that was inhibited by pretreatment with cyclosporin A or tacrolimus. In contrast in human dermal ®broblasts, TPA plus ionomycin or TPA did not signi®cantly alter the proportion of nuclear-associated NFAT1. These data provide the ®rst evidence that calcineurin is functionally active in human keratinocytes inducing nuclear translocation of NFAT1 and also indicate that regulation of NFAT1 nuclear translocation in skin is cell type spe-ci®c. Inhibition of this pathway in epidermal keratinocytes may account, in part, for the therapeutic effect of cyclosporin A and tacrolimus in skin diseases such as psoriasis. Key words: calcium/cell differentiation/immunophilin/signal transduction/tacrolimus. J Invest Dermatol 118: 779±788, 2002 P soriasis is a chronic, disabling skin disease, which affects approximately 2% of the population in Western countries. Psoriatic plaques are characterized by increased keratinocyte proliferation leading to epidermal hyperplasia, abnormal keratinocyte differentiation, in-®ltration of epidermis and dermis by activated lymphocytes and neutrophils, and tortuous and dilated upper dermal blood vessels.
Systemic cyclosporin A (CsA) and tacrolimus are effective treatments for psoriasis (Ellis et al, 1986; Jegasothy et al, 1992) . Their widespread use is, however, limited by side-effects, (Powles et al, 1998) .
CsA and tacrolimus are immunosuppressive drugs that inhibit T cell activation through well-characterized pathways, established through biochemical, genetic, and crystallographic studies (Rao et al, 1997) . Speci®cally, CsA and tacrolimus bind to intracellular proteins, principally cyclophilin A and FKBP12, respectively, and thereby inhibit the phosphatase calcineurin. This leads to an increased phosphorylation of calcineurin substrates, particularly the family of nuclear factor of activated T cells (NFAT) nuclear transcription factors, preventing translocation of NFAT to the nucleus. As NFAT is essential for interleukin-2 (IL-2) gene transcription, IL-2 production and T cell activation is inhibited (Rao et al, 1997) . In addition to their role in immune activation, calcineurin and members of the NFAT family are known to be expressed relatively selectively in a variety of nonimmune cells including heart, muscle, and brain (Rao et al, 1997; Chin et al, 1998; Molkentin et al, 1998; Graef et al, 1999) and exert diverse effects such as regulation of cardiac hypertrophy, blood vessel assembly, muscle differentiation, and memory formation (Rao et al, 1997; Chin et al, 1998; Aramburu et al, 2000; Graef et al, 2001; Malleret et al, 2001) .
The ef®cacy of CsA and tacrolimus has been used as a powerful argument to support the fundamental role of T cells in the pathogenesis of psoriasis. Several studies indicate, however, that CsA exerts direct effects in skin independent of its action on T cells. For example, CsA and tacrolimus inhibit proliferation of cultured keratinocytes at therapeutically relevant concentrations (Fisher et al, 1988; Cooper et al, 1992) , although whether CsA exerts an effect on human keratinocyte proliferation in vivo remains controversial. In mouse skin, however, topical CsA inhibits 12-O-tetradecanoylphorbol-13-acetate (TPA) induced epidermal hyperplasia, as well as leukocyte in®ltration and keratinocyte-derived transglutaminase activity (Gupta et al, 1989) . Furthermore, CsA inhibits epidermal proliferation in nude mice (Ramirez-Bosca et al, 1990) and inhibits TPA-induced in¯ammation in SCID mice, in the absence of functioning T cells . CsA and tacrolimus both induce hair growth (Watanabe et al, 1991; Taylor et al, 1993; Yamamoto-Hino et al, 1994) and topical tacrolimus stimulates hair growth in SCID mice (Yamamoto-Hino et al, 1994) . CsA also inhibits antigen presentation by Langerhans cells (Furue and Katz, 1988) and inhibits neutrophil chemotaxis (Pigatto et al, 1990) . If CsA and tacrolimus are having local pharmacologic effects in skin, independent of T cells, this may have important implications for our understanding of the pathophysiology of psoriasis. In this study, we have determined the expression pattern of components of the calcineurin/NFAT signaling pathway in normal skin and psoriasis. We also investigated whether CsA and tacrolimus inhibit activation of calcineurin/NFAT in cultured human keratinocytes at therapeutically relevant doses.
MATERIALS AND METHODS
Materials CsA and tacrolimus were provided by Novartis Pharma (Basle, Switzerland) and Fujisawa Pharmaceutical (Osaka, Japan), respectively. Tacrolimus was also obtained from Af®nity Research Products (Exeter, U.K.). Antibodies used were: rabbit polyclonal antibody to cyclophilin A (Calbiochem-Novabiochem, Nottingham, U.K.); murine monoclonal antibody to FKBP12 clone #2C1 (Dr. Kobayashi, Fujisawa, Japan, and from PharMingen, CA); murine monoclonal antibodies to calcineurin B (regulatory subunit) (Upstate Biotechnology, NY), calcineurin A (catalytic subunit) (PharMingen), CD1a (PharMingen), and rabbit polyclonal antibody to NFAT1 (Upstate Biotechnology). HA-murine NFAT1 1-460-GFP (in pEGFP.N1) was a kind gift from Dr. A Rao (Lopez-Rodriguez et al, 1999) .
Western blotting Cells were lyzed in 2 Q sodium dodecyl sulfate (SDS) sample buffer (125 mM Tris-HCl, pH 6.8, 0.05% bromophenyl blue, 4% SDS, 20% glycerol, and 10% b-mercaptoethanol). Equal protein quantities of samples and enhanced chemiluminescence molecular weight markers (Amersham, Bucks, U.K.) were electrophoresed through 10% polyacrylamide gels, and Western blotting was performed as described previously (Todd and Reynolds, 1998) , using anticyclophilin A (1:1000), anti-FKBP12, anticalcineurin B (1:1000), or anti-NFAT1 (1:5000) antibodies.
Subjects and skin biopsies The local Ethical Committee approved the study protocol and all subjects gave written informed consent prior to entering the study. Three normal volunteers (one male, two females, mean age 41 y) and seven patients (®ve males, two females, mean age 36 y) with stable plaque psoriasis were initially recruited. Patients were excluded if they had received systemic antipsoriatic, ultraviolet B, or psoralen plus ultraviolet A therapy during the last 3 mo, or topical medication, apart from emollients, during the last 2 wk. Paired 6 mm punch biopsies were taken, under local anesthesia, from the edge of psoriatic plaques (lesional) and nonlesional (uninvolved) skin (at least 2 cm from the edge of plaque) on the lower back/buttock, embedded in optimal cutting temperature compound, frozen, and stored at ±70°C. For the NFAT studies, skin biopsies were obtained from a further 12 patients with psoriasis (seven males, ®ve females, mean age 48 y) and a further eight normal volunteers (seven males, one female, mean age 21 y).
Immunohistochemistry of skin biopsies, cultured human keratinocytes, and dermal ®broblasts Five micron frozen sections of human skin were immunostained as described previously using antibodies to cyclophilin A (1:1500), FKBP12 (1:400), calcineurin B (1:100), or NFAT1 (1:500), an avidin-biotin immunoperoxidase technique, and Ni-diaminobenzidine as the color substrate. Sections were counterstained with methyl green. The degree of staining was assessed on a semiquantitative scale and the predominant pattern of intracellular staining was assessed as cytoplasmic, membranous, or nuclear. Blinding was not possible due to the characteristic morphologic features of lesional psoriatic biopsies. For double-labeling experiments, 5 mm frozen sections of human skin were incubated sequentially with anti-CD1a antibody (1:10), biotinylated horse antimouse IgG antibody (1:100), strepavidin Oregon Green 488 (Molecular Probes, OR) 1:100, anti-FKBP12 antibody (1:500), and Alexa-568-labeled goat antimouse IgG (1:100) (Molecular Probes, OR). Oregon Green 488 and Alexa 568 were excited using the 488 nm line supplied by the Ar ion laser and the 543 nm line supplied by the HeNe laser, respectively. Fluorescence emission was monitored line by line, using the sequential scanning mode to minimize any possible crosstalk, and Z series of images were captured using a Leica TCS SP II confocal laser microscope (Leica Microsystems, Milton Keynes, U.K.).
Keratinocytes and ®broblasts were isolated from normal human skin obtained from plastic and pediatric surgical procedures. Keratinocytes Figure 1 . Cyclophilin A, FKBP12, calcineurin B, and NFAT1 are expressed by cultured human keratinocytes. Cell lysates were prepared from cultured keratinocytes, separated by SDS polyacrylamide gel electrophoresis, and immuno blotted with antibodies against cyclophilin A (CyPA), calcineurin B (CaNB), FKBP12, or NFAT1, as indicated. Results from two samples derived from independent donors (lanes 1, 2) are shown. The relative molecular mass of protein markers is indicated to the left of the blots. were cultured in T75¯asks in MCDB-153 (Sigma, Poole, U.K.) serumfree medium with a calcium concentration of 70 mM, supplemented with ethanolamine (6.1 ml per l), phosphoethanolamine (14 mg per ml), hydrocortisone (0.18 mg per ml), insulin (5 mg per ml), transferrin (5 mg per ml), epidermal growth factor (10 ng per ml), penicillin G (5 IU per ml), streptomycin (5 mg per ml), and amino acids, essentially as described previously (Todd and Reynolds, 1998) . Keratinocytes were expanded by serial passage and used for experiments between passages 2 and 3. Fibroblasts were cultured in T75¯asks in Dulbecco's modi®ed Eagle's medium (DMEM) with 10% fetal bovine serum (Sigma, Dorset, U.K.). Cells were seeded onto glass coverslips, cultured until 50%±70% con¯uent, and then treated with agonists as speci®ed. At de®ned time points, cells were ®xed and permeabilized with 4% paraformaldehyde and 0.2% Triton X-100, and incubated sequentially with antibodies to calcineurin A (1:100), calcineurin B (1:500), Oregon Green 488-labeled or Alexa-568-labeled secondary antibodies (1:300) (Molecular Probes, OR), and propidium iodide (50 mg per ml, Sigma). The number of cells showing positive nuclear staining was counted under 60Q magni®cation using epi¯uorescence microscopy. In the studies on keratinocytes, a minimum of 75 cells in three independent experiments (225 cells in total) were assessed at each time point. Blinding was dif®cult due to the characteristic morphologic features of cells treated with TPA or raised extracellular calcium, but for the experiments examining the dosage effects of CsA and tacrolimus, slides were coded and the observer was masked from the treatment conditions. In the studies on ®broblasts, the observer was again masked from the treatment conditions and a minimum of 50 cells in three independent experiments (150 cells in total) were assessed at each time point. Z series of images were captured on a Biorad MRC 600 scanning laser confocal microscope (Bio-Rad Laboratories, Herts, U.K.) with a Kr/Ar laser. Fluorescence emission of Oregon Green, excited by the 488 nm laser line, and Alexa 568/ propidium iodide, excited by the 568 nm laser line, were captured sequentially to minimize crosstalk.
Images were processed using Confocal Assistant (Version 4.02, Todd Clark Brelje) and Adobe Photoshop (San Jose, CA). Mid-cell image sections are shown. Isotype IgG or polyclonal rabbit serum were included at equivalent concentrations to the primary antibodies in immunohistochemical and immuno¯uorescence studies as negative controls.
Transfection of epidermal human keratinocytes Three Q 10 4 keratinocytes were seeded onto 22 mm 2 sterile coverslips and cultured until approximately 60%±70% con¯uent. Cells were then switched to antibiotic-free medium and transfected with HA-NFAT1-GFP or pEGFP.N1 (Clontech, Hampshire, U.K.) using Lipofectamine Plus (Gibco BRL Life Technologies, Paisley, U.K.), according to the manufacturer's instructions. In brief, for each coverslip, 2 mg of DNA and 6 ml of Plus reagent were diluted in serum-free, antibiotic-free MCDB-153 medium and incubated for 15 min at room temperature. Pre-complexed DNA and 4 ml of diluted Lipofectamine were combined, incubated for 15 min, and then added to cells for 3 h at 37°C. To maximize cell growth, medium was then replaced with fresh serum-free, antibiotic-free medium MCDB-153. After 24 h, transfected cells were transferred to a temperature-controlled perfusion chamber (Intracel, Royston, U.K.), maintained at 37°C, and visualized following excitation of green¯uorescent protein by the 488 nm laser line using a Leica TCS SP II confocal laser microscope (Leica Microsystems).
Statistical analysis
To compare the effect of speci®ed treatments on the number of cells showing positive nuclear immunostaining, c 2 analysis was used. To assess the dosage effects of CsA on NFAT1 translocation, c 2 analysis of trend was performed. Fisher's exact test was used to compare the proportion of subjects showing nuclear immunostaining of NFAT1 in basal and suprabasal keratinocytes. Data were analyzed using Arcus Quickstat (Biomedical Version 1.0).
RESULTS
Cyclophilin A, FKBP12, calcineurin, and NFAT1 are coexpressed in cultured human keratinocytes and in normal and psoriatic skin in vivo Western blotting showed that cultured human keratinocytes coexpress cyclophilin A, FKBP12, calcineurin B, and NFAT1 (Fig 1) . These experiments demonstrated that the antibodies detect appropriate molecular weight proteins in skin cells (»18 kDa for cyclophilin A, »12 kDa for FKBP12, »19 kDa for calcineurin B, and »130 kDa for NFAT1) and do not signi®cantly crossreact with other proteins in these cell lysates.
Immunohistochemical studies of normal human and psoriatic skin showed prominent expression of cyclophilin A, FKBP12, calcineurin B, and NFAT1 in epidermal keratinocytes (Fig 2A) together with expression in dermal ®broblasts. Langerhans cells within the epidermis also expressed cyclophilin A, FKBP12, and calcineurin B in normal and psoriatic skin (Fig 3) . Calcineurin B and NFAT1 immunostaining was also observed in vascular endothelial cells, skin appendages, and within the dermal in¯ammatory cell in®ltrate in psoriasis (Fig 2A) . High levels of cyclophilin A expression were observed within the cytoplasm of basal epidermal keratinocytes, with reduced levels within the more differentiated, suprabasal cells (Fig 2A) . Cytoplasmic and membrane patterns of calcineurin B expression were observed in keratinocytes (Fig 2A) . In contrast to cyclophilin A and calcineurin B, FKBP12 showed nuclear localization in epidermal keratinocytes and dermal ®broblasts, and, within epidermis, expression appeared reduced in high suprabasal keratinocytes (Fig 2A) . No consistent differences were observed between normal skin, lesional psoriatic skin, or nonlesional psoriatic skin with respect to cyclophilin A, FKBP12, and calcineurin expression ( Fig 2A) . NFAT1 showed cytoplasmic and nuclear localization in epidermal keratinocytes. As a negative control, nonimmune rabbit serum at a similar dilution to NFAT1 was included in the immunostaining protocol and showed no positive immunoreactivity ( Fig 2B) . NFAT1 appeared predominantly nuclear in normal basal keratinocytes but showed reduced nuclear and increased cytoplasmic expression in differentiating suprabasal cells (Fig 2A, B) . Increased nuclear immunostaining in suprabasal keratinocytes was observed in lesional and to a lesser extent in nonlesional psoriatic skin compared to normal controls (Fig 2A, B) . The proportion of subjects showing predominantly nuclear-associated NFAT1 immunostaining in suprabasal keratinocytes was signi®cantly increased in lesional psoriatic skin biopsies (12 of 12, p = 0.001) and nonlesional psoriatic skin biopsies (8 of 12, p = 0.03) compared to normal skin (1 out of 8).
Nuclear translocation of NFAT1 in human keratinocytes is inhibited by CsA and tacrolimus As calcineurin activation in T cells results in translocation of NFAT1 and calcineurin to the nucleus (Rao et al, 1997) , we next studied the intracellular distribution of the NFAT1 and calcineurin in cultured keratinocytes to determine whether this pathway is functionally active in these cells. In untreated keratinocytes or cells treated with vehicle, NFAT1 was found predominately in the cytoplasm ( Fig 4A) (8.8% and 16.0% nuclear positivity, respectively; n = 225 cells) ( Fig 5A) . Because activation of calcineurin requires a sustained rise in intracellular calcium and CsA inhibits TPAinduced changes in mouse skin , we initially treated cultured human keratinocytes with TPA (50 nM) plus ionomycin (1 mM), agonists that induce keratinocyte differentiation (Zhao et al, 1992) . We found increased nuclear localization of NFAT1 by 15 min (58.4% nuclear positivity), which was maximal at 4 h (84.4% nuclear positivity) and persisted to 18 h (81.8% nuclear positivity) (n = 225 cells) ( Figs 4A, 5A) . TPA (50 nM) alone or increasing extracellular calcium ([Ca 2+ ] o ) from 70 mM to 1.5 mM also cause a rise in intracellular calcium (Sharpe et al, 1993) and induce keratinocyte differentiation, and both these agonists resulted in increased nuclear localization of NFAT1 ( Fig 4A) with similar kinetics to TPA plus ionomycin ( Fig 5A) .
To con®rm that our assessment of NFAT1 subcellular localization by immuno¯uorescence had not been affected by ®xation and to further validate the speci®city of the NFAT1 antibody that we had utilized, we transfected keratinocytes with HA-NFAT1-GFP, examined the cellular localization of HA-NFAT1-GFP by confocal microscopy, and monitored single cells in real time. These studies showed that HA-NFAT1-GFP was predominantly localized to the cytoplasm in untreated keratinocytes (Fig 6) and showed a similar distribution to endogenous NFAT1 detected by immuno¯uorescence ( Fig 4A) . Treatment with TPA (50 nM) plus ionomycin (1 mM) for 1 h resulted in translocation of HA-NFAT1-GFP to the nucleus (Fig 6) . Similar responses were observed following treatment of keratinocytes, transfected with HA-NFAT1-GFP, with Human keratinocytes were cultured on coverslips in low calcium MCDB-153 medium (control) and then treated with dimethyl sulfoxide (DMSO) (vehicle control) or TPA (50 nM) plus ionomycin (1 mM) or [Ca 2+ ] o (raised extracellular calcium, 1.5 mM) for 4 h. Some coverslip cultures were pretreated with cyclosporin A (CsA) 1 mM for 1 h, as indicated. Cells were ®xed in 4% paraformaldehyde and permeabilized with 0.2% Triton X-100. Immuno¯uorescence labeling was performed as described in Materials and Methods. In (A) cells were labeled with anti-NFAT1 antibody (Oregon Green 488) and propidium iodide (PI) and in (B) cells were double-labeled with anticalcineurin B (Alexa 568), and anticalcineurin A (Oregon Green 488). Cells were then visualized using confocal microscopy. The images shown are mid-cell sections. These results are representative of three experiments on keratinocytes derived from three independent donors. Scale bar: 25 mM. VOL. 118, NO. 5 MAY 2002 TPA and raised extracellular calcium (1.5 mM) (data not shown). The empty GFP vector was distributed evenly throughout the cell and there was no change in its cellular location following treatment of keratinocytes with TPA plus ionomycin, TPA, or raised extracellular calcium (data not shown).
We next determined whether CsA and tacrolimus inhibited translocation of endogenous NFAT1 in human keratinocytes. We found that CsA (1 mM) and tacrolimus (1 mM) signi®cantly inhibited nuclear translocation of NFAT1 induced by TPA plus ionomycin, TPA, and increased extracellular calcium at 4 h ( Fig 4A and Table I ). The comparisons of the data presented in Table I re¯ect the structure of the data and the hypotheses being tested. In further experiments, we assessed the effects of a range of CsA and tacrolimus doses (1 nM, 10 nM, 100 nM, and 1 mM) on NFAT1 nuclear translocation. The data in Table II show that 100 nM CsA and 100 nM tacrolimus inhibited nuclear translocation of NFAT1 induced by TPA/ionomycin and TPA by approximately a third but did not appear to affect nuclear translocation of NFAT1 induced by increased extracellular calcium. Analysis of trend indicates a signi®cant dosage effect for both CsA and tacrolimus on nuclear translocation of NFAT1 induced by TPA/ionomycin (p < 0.0001), TPA (p < 0.0001), and increased extracellular calcium (p < 0.0001).
Translocation of calcineurin to the nucleus and plasma membrane in human keratinocytes is inhibited by CsA and tacrolimus Comigration of calcineurin to the nucleus is required to maintain NFAT in a dephosphorylated state, prevent export of NFAT from the nucleus, and sustain activation of NFAT target genes (Shibasaki et al, 1996; Zhu and McKeon, 1999) . We therefore investigated whether nuclear translocation of NFAT1 was accompanied by comigration of calcineurin A and B subunits in human keratinocytes. Figure 4(B) shows that TPA, TPA plus ionomycin, and increased extracellular calcium induced translocation of calcineurin A and B to the nucleus. The time course of calcineurin nuclear translocation ( Fig 5B) appeared to lag slightly behind that for NFAT1 ( Fig 5A) . For example, in cells treated with TPA plus ionomycin, we observed 4% nuclear positivity at 15 min that increased to 15.3% at 2 h but was not maximal until 18 h (88.7% nuclear positivity) (n = 225 cells). In cells exposed to TPA or raised extracellular calcium, the time course of increasing calcineurin nuclear positivity were similar up to 4 h. In cells exposed to raised extracellular calcium, however, the degree of nuclear-associated calcineurin had returned towards baseline by 18 h, in contrast to cells treated with TPA or TPA plus ionomycin ( Fig 5B) . CsA (1 mM) inhibited nuclear translocation of calcineurin A and B at 4 h ( Fig 4B, Table I ). In separate experiments, tacrolimus also inhibited nuclear translocation of calcineurin A and B at 4 h (data not shown). We observed increased association of calcineurin A and B with the plasma membrane, most marked at 4 h, following treatment with TPA plus ionomycin, TPA, and increased extracellular calcium, which was inhibited by pretreatment with CsA ( Fig 4B) . In addition, CsA inhibited the shape change and¯attening of keratinocytes that occurred in response to increased extracellular calcium at 4 h ( Fig 4B) .
TPA plus ionomycin or TPA do not induce nuclear translocation of NFAT1 in human dermal ®broblasts In order to assess whether activation of calcineurin/NFAT in human skin was dependent on cellular context, we investigated NFAT1 nuclear localization in cultured human dermal ®broblasts. In contrast to human keratinocytes, NFAT1 appeared evenly distributed between the cytoplasm and nucleus in unstimulated cells (Fig 7) . Furthermore, treatment of ®broblasts with TPA plus ionomycin or TPA for between 2 h and 18 h did not signi®cantly alter the cellular distribution of NFAT1 or the proportion of cells showing nuclear NFAT1 positivity (Fig 7 and Table III ). We next determined the effect of CsA (1 mM) or tacrolimus (1 mM) on NFAT1 localization in these cells. CsA (1 mM) for 2 h or 4 h did not signi®cantly alter the proportion of ®broblasts displaying NFAT1-immunostained nuclei ( Table III, Fig 7) . Treatment of ®broblasts with CsA (1 mM) for 18 h, however, reduced the percentage of NFAT1 positively immunostained nuclei nuclear from 97% to 83% (p`0.0001). Tacrolimus for 2 h reduced the percentage of NFAT1 positively immunostained nuclei nuclear from 97% to 91% (p = 0.03) (Fig 7, Table III ) but no signi®cant effect was observed at 4 h or 18 h. Overall, the effects of CsA and tacrolimus appeared less compared to equivalent doses in keratinocytes and showed kinetic differences. These data indicate that dermal ®broblasts and keratinocytes show distinct differences in their activation pattern of calcineurin/NFAT1 and differ in their responsiveness to CsA and tacrolimus.
DISCUSSION
These studies show for the ®rst time that nonimmune cells in normal and psoriatic skin express the key components of the calcineurin/NFAT signal transduction pathway, speci®cally the principal CsA and tacrolimus binding proteins cyclophilin A and FKBP12, respectively, the phosphatase calcineurin, and the transcription factor NFAT1, that mediate downstream signaling of CsA and tacrolimus in T cells. Expression of all four proteins was prominent in keratinocytes. Langerhans cells also expressed cyclophilin A, FKBP12, and calcineurin B. As nuclear localization of NFAT provides evidence of calcineurin activation (Kiani et al, 2000) , our observation of increased nuclear localization of NFAT1 in suprabasal keratinocytes of psoriatic epidermis is particularly interesting. Our studies of primary cultured keratinocytes provide the ®rst description of the subcellular localization of endogenous calcineurin A, calcineurin B, and NFAT1 in these cells. Furthermore, we have shown that calcineurin is functionally active in human keratinocytes by demonstrating nuclear translocation of endogenous NFAT1 in response to differentiation stimuli that is inhibited by CsA and tacrolimus in a dose-dependent manner, at therapeutically relevant doses (Ellis et al, 1991; Cooper et al, 1992) . Recently, Nishio et al have also reported immunolocalization of calcineurin and FKBP12 in normal human epidermal keratinocytes (Nishio et al, 2000) . Taken together, these data identify a potential local, T-cell-independent, mechanism of action for CsA and tacrolimus in psoriasis that may contribute, at least in part, to the therapeutic effects of these drugs.
Topical CsA is ineffective in psoriasis as it is not absorbed, although intralesional CsA improves psoriasis (Burns et al, 1992) . Tacrolimus is a smaller molecule that is able to induce clearance of psoriasis following topical application under occlusion (Remitz et al, 1999) . Systemic CsA rapidly inhibits epidermal IL-1 and IL-8 expression in psoriatic skin, prior to clinical improvement (Prens et al, 1995) , suggesting that modulation of the keratinocyte cytokine network may play a role in the therapeutic effect of CsA in psoriasis. Further work is required, however, to dissect the relative contri-bution of inhibiting NFAT pathways in lymphocytes, Langerhans cells, and keratinocytes to the therapeutic effect of CsA and tacrolimus in psoriasis. Although T cells have been implicated in the pathogenesis of psoriasis, certain clinical patterns, such as a linear form occurring in Blaschko's lines suggesting genetic mosaicism or some epigenetic change in epidermis (Happle, 1991) , an increased rate of keratinocyte proliferation in uninvolved psoriatic skin compared to normal skin, and hyperresponsiveness of uninvolved psoriatic skin to proliferation stimuli (Wiley and Weinstein, 1979) , remain, however, hard to explain, on the basis of a T-cell-driven process alone. Furthermore, supernatants from T cells cloned from psoriatic plaques stimulated proliferation of``stem cells'' from nonlesional psoriatic skin but not stem cells from normal skin (Bata-Csorgo et al, 1995) , suggesting an intrinsic difference between psoriatic and normal keratinocytes. Moreover, therapeutic agents targeted to interfere speci®cally with T cell function (including the fusion protein DAB 389 IL-2, the soluble chimeric protein cytotoxic T-lymphocyte-associated antigen-4[CTLA-4], humanized anti-CD4 monoclonal antibody, and a humanized monoclonal antibody to CD11a) show variable ef®cacy as antipsoriatic treatments (Bagel et al, 1998; Abrams et al, 1999; Gottlieb et al, 2000a, b) and appear only partially effective when assessed in randomized controlled trials (Bagel et al, 1998; Gottlieb et al, 2000a, b) . Although a partial clinical response may represent incomplete blockade of T cell function, an alternative explanation is that inhibition of keratinocyte activation is also required for clearance of psoriasis.
The family of NFAT nuclear transcription factors comprises ®ve members with alternative splicing resulting in several isoforms. NFAT1, NFAT2, NFAT3, and NFAT4 are structurally and functionally related and undergo translocation to the nucleus following dephosphorylation by calcineurin (Rao et al, 1997; Kiani et al, 2000) . NFAT family members display unique and relatively narrow tissue patterns of protein expression (Rao et al, 1997; Kiani et al, 2000) and show temporal regulation of expression during embryogenesis. For example, NFAT1 protein is present in lymphocytes, lymphoid organs (thymus and spleen), olfactory epithelium, endothelial cells, but not in small intestine, liver, kidney, cardiac, or skeletal muscle (Wang et al, 1995; Rao et al, 1997) ; NFAT4 is highly expressed in thymocytes and smooth muscle VOL. 118, NO. 5 MAY 2002 (Oukka et al, 1998 Stevenson et al, 2001) ; and transient expression of NFAT2 within the nuclei of endocardial cells is required for heart valve formation during embryogenesis (de la Pompa et al, 1998; Ranger et al, 1998) . NFAT binds only weakly to DNA and requires a partner protein (e.g., AP1 or GATA4), which varies among cell types, in order to initiate transciptional activation (Crabtree, 1999) . In addition, distinctive mechanisms of nuclear localization among NFAT family members have been identi®ed (Graef et al, 1999) . Therefore a number of independent mechanisms may contribute to the tissue and cellular speci®city of responses. As NFAT1 mRNA is detectable in mouse skin (Northrop et al, 1994) , we focused our initial studies on NFAT1, but we have also detected mRNA for NFAT2, NFAT3, and NFAT4 in cultured human keratinocytes (unpublished observations). The function of calcineurin/NFAT in human skin is currently unknown. Activation of calcineurin/NFAT by TPA, TPA and ionomycin, and raised extracellular calcium, however, suggests that this pathway plays a role in regulating keratinocyte differentiation. Santini et al have very recently shown that calcineurin regulates the expression of mouse keratinocyte differentiation markers and the cyclin-dependent kinase inhibitor p21 WAF1 through a mechanism that appears to involve an interaction between NFAT1/NFAT2 and the Sp1/Sp3 transcription factors (Santini et al, 2001) . Nuclear localization of NFAT provides evidence of calcineurin activation, and furthermore, the proportion of NFAT in the nucleus is thought to be a re¯ection of the overall level of calcineurin activity (Kiani et al, 2000) . Increased nuclear NFAT1 in psoriatic skin may therefore account for the increased suprabasal expression of p21 WAF1 observed in psoriasis (Healy et al, 1995) , although the absence of ®laggrin expression in psoriatic plaques (Bernard et al, 1988) is not readily explained. Previous work in BHK ®broblasts has indicated that comigration of calcineurin to the nucleus is required to maintain GFP-NFAT4 in the nucleus and prevent its export (Shibasaki et al, 1996; Zhu and McKeon, 1999) . In contrast, our time course studies of endogenous calcineurin and NFAT1 suggest that nuclear translocation of calcineurin lags slightly behind that of NFAT1. Furthermore, although the degree of calcineurin nuclear positivity had returned towards baseline following exposure to raised extracellular calcium for 18 h, NFAT1 nuclear positivity was maintained at this time point. Our studies of calcineurin and NFAT1, however, were performed on keratinocytes derived from different donors. Further work utilizing, for example, GFP-tagged proteins is therefore required to con®rm these results and we are in the process of preparing the appropriate constructs.
Sustained mobilization of calcium is required for activation of NFAT. The recent studies of NFAT4 in mouse smooth muscle cells by Stevenson et al, however, indicate that prolonged elevation of intracellular calcium may not be suf®cient (Stevenson et al, 2001) and that the calcium signaling mechanisms involved in activating NFAT are cell type speci®c. Within the basal layer, calcium is localized primarily to mitochondria and the nucleus; more abundant intracellular deposits are found in upper epidermal layers and calcium is thought to regulate both keratinocyte growth and differentiation (Menon and Elias, 1991) , although the mechanisms involved are not well understood. Increased calcium within the cytosolic and nuclear compartments of keratinocytes (Menon and Elias, 1991) and increased calmodulin activity (Tucker et al, 1984; Mizumoto et al, 1985) in psoriatic epidermis may contribute to calcineurin activation and increased nuclear localization of NFAT1 in psoriatic skin. Our studies in cultured keratinocytes have shown that TPA plus ionomycin and raised extracellular calcium, agents that induce sustained rises in intracellular calcium, result in translocation of NFAT1 and calcineurin to the nucleus, which is inhibited by CsA and tacrolimus. Induction of nuclear translocation of NFAT1 by TPA alone has not been observed in other cell types, although in human keratinocytes prolonged treatment with TPA leads to a sustained rise of intracellular calcium (Sharpe et al, 1989) and terminal differentiation. Although NFAT1 is also expressed by human dermal ®broblasts, we did not observe translocation of NFAT1 to the nucleus upon stimulation with TPA or TPA plus ionomycin. Furthermore, the in¯uence of CsA and tacrolimus on the proportion of NFAT1 localized to the nucleus in human ®broblasts was less marked than in keratinocytes. These data underscore that the responsiveness and regulation of the calcineurin/NFAT pathway in human skin is cell type speci®c. The functional consequences of NFAT activation in skin remain to be fully explored, but genes expressed by keratinocytes and known to be regulated by NFAT include granulocyte macrophage colony stimulating factor, tumor necrosis factor a, FasL, and intercellular adhesion molecule 1 (Kiani et al, 2000) .
The intracellular distribution of cyclophilin A, FKBP12, and calcineurin B varies among cell types. For example, calcineurin B was found predominantly in the cytosolic fraction in human T cells (Le Hir et al, 1995) , whereas in brain a signi®cant portion was located in the membrane fraction (Klee et al, 1988) . We found that localization of calcineurin B to the keratinocyte cell membrane was a prominent feature in sections of normal and psoriatic skin and we observed translocation of calcineurin B to the plasma membrane in response to agonists that induce a rise in intracellular calcium. Distinct mechanisms regulate targeting of calcineurin to speci®c cellular locations and substrates. Although the mechanisms regulating targeting of calcineurin to the plasma membrane are not well understood, calcineurin B contains a myristoylation signal (Klee et al, 1988) and calcineurin A binds to the anchoring protein AKAP79 that attaches to the plasma membrane . In contrast to calcineurin B, FKBP12 was predominantly localized to the nucleus in epidermal keratinocytes and dermal ®broblasts. Nuclear localization of FKBP12 has been described in human mononuclear cells and in T cells by immunostaining and Western analysis (Kobayashi et al, 1993; Le Hir et al, 1995) . Interestingly, alteration in nuclear localization and intracellular distribution of FKBP12 was observed in mononuclear cells and in Jurkat T cells following stimulation and serum deprivation (Kobayashi et al, 1993) . Variation in the subcellular distribution and level expression of immunophilins and calcineurin in different cell types may contribute to the diversity of functional effects among tissues in response to CsA and tacrolimus. Although calcineurin appears to be expressed in most tissues studied, the level of expression varies signi®cantly among tissues (Crabtree, 1999) . Evidence indicates that the response of different cells and tissues to CsA and tacrolimus depends on the level of calcineurin expressed and is less in cells expressing high levels of calcineurin (Crabtree, 1999) .
There is concern about the long-term side-effects, particularly nephrotoxicity, from the use of systemic CsA and tacrolimus for treating psoriasis (Powles et al, 1998) . Although the mechanism of renal damage remains to be fully de®ned, inhibition of calcineurin activity in the kidney is thought to play an important role (Tumlin, 1997) . If these drugs are exerting important therapeutic effects locally in skin through inhibition of NFAT activation, optimization of topical delivery or development of topical drugs that speci®cally target NFAT may result in important therapeutic advances. Figure 7 . TPA and ionomycin do not induce nuclear translocation of NFAT1 in human dermal ®broblasts. Human dermal ®broblasts were cultured on coverslips in DMEM and 10% fetal bovine serum and then treated with DMSO (vehicle control), TPA (50 nM) plus ionomycin (1 mM), ionomycin (1 mM), CsA (1 mM), or tacrolimus (1 mM) for the indicated times. Cells were ®xed in 4% paraformaldehyde and permeabilized with 0.2% Triton X-100. Immunouorescence labeling was performed with anti-NFAT1 antibody (Oregon Green 488) and propidium iodide (PI) as described in Materials and Methods. Cells were then visualized using confocal microscopy. These results are representative of three experiments on ®broblasts derived from three independent donors. Scale bar: 25 mM. Supported by grants from the Sir Jules Thorne Charitable Trust (96/12 A) and the Wellcome Trust (061178). NJR is a recipient of a Wellcome Research Leave Award for Clinical Academics. We thank Professor John Matthews for his advice on statistical analysis and Dr. Peter Farr and Dr. Mark Birch-Machin for their critical review of the manuscript.
